STOCK TITAN

Abbvie Inc - ABBV STOCK NEWS

Welcome to our dedicated news page for Abbvie (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbvie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbvie's position in the market.

News
Rhea-AI Summary
AbbVie Inc. declares a quarterly cash dividend of $1.48 per share, payable on November 15, 2023. The company has increased its dividend by 270% since 2013 and is a member of the S&P Dividend Aristocrats Index.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
dividends
-
Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, has launched crowdfunding campaigns for women entrepreneurs who received grants through the BOTOX® Cosmetic and IFundWomen program. The entrepreneurs participated in a Crowdfunding Accelerator Program and are now seeking additional funding for their businesses. Allergan Aesthetics aims to close the 'Confidence Gap' by supporting women-owned businesses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
Rhea-AI Summary
AbbVie to participate in Morgan Stanley Annual Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, published results from a year-long analysis showing that 90.5% of patients were satisfied with the natural look achieved with BOTOX® Cosmetic for upper facial lines. Over 80% of patients maintained their satisfaction throughout the 12-month study period. More than half of patients reported an improvement in self-perceived appearance and psychological well-being.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
-
Rhea-AI Summary
AbbVie submits applications for new indication of risankizumab for ulcerative colitis treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
Rhea-AI Summary
AbbVie's AQUIPTA® (atogepant) has been approved by the European Commission for the prophylaxis of migraine in adults who have four or more migraine days per month. This makes AQUIPTA the first and only once-daily oral CGRP receptor antagonist treatment for both chronic and episodic migraine in the European Union. The approval is based on two Phase 3 studies that showed a statistically significant reduction in mean monthly migraine days with AQUIPTA compared to placebo. Migraine is a debilitating disease that affects daily activities and imposes a significant burden on individuals and healthcare systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
Rhea-AI Summary
Allergan Aesthetics (NYSE: ABBV) celebrates the first ever JUVÉDERM® Day on August 16, 2023, offering exclusive savings and offers to new and loyal consumers through the Allē loyalty program. The celebration recognizes the JUVÉDERM® Collection of Fillers as the number one chosen dermal fillers in the U.S. Consumers can enjoy BOGO gift cards and triple Alle points for treatments with the Allergan Aesthetics portfolio of products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
-
Rhea-AI Summary
AbbVie (NYSE:ABBV) announced strong second-quarter financial results, with diluted EPS of $1.14 on a GAAP basis, a 123.5% increase, and net revenues of $13.865 billion, a 4.9% decrease. The company raised its 2023 adjusted diluted EPS guidance to $10.90 - $11.10.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
earnings
-
Rhea-AI Summary
AbbVie (NYSE: ABBV) and Calibr have announced an expanded strategic collaboration to advance innovative preclinical and early-stage clinical assets in immunology, oncology, neuroscience, and other areas. The partnership aims to develop potential new therapeutics and explore novel technologies for breakthrough medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
Rhea-AI Summary
AbbVie announced that the British Journal of Dermatology has published results from a Phase 4 study comparing SKYRIZI® (risankizumab) to Otezla® (apremilast) for the treatment of adult patients with moderate plaque psoriasis. The study showed that significantly more patients achieved the co-primary endpoints of PASI 90 and sPGA 0/1 at Week 16 with risankizumab compared to apremilast. Higher treatment satisfaction scores were also reported for risankizumab. The study demonstrated the efficacy and safety of SKYRIZI and provides evidence supporting it as a treatment option for adults with moderate psoriasis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
clinical trial
Abbvie Inc

NYSE:ABBV

ABBV Rankings

ABBV Stock Data

319.34B
1.76B
0.12%
71.89%
0.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
North Chicago

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.